Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Analysts at Gabelli issued their FY2019 EPS estimates for Zimmer Biomet Holdings in a report issued on Thursday. Gabelli analyst J. Tsai forecasts that the medical equipment provider will post earnings per share of $9.75 for the year. Gabelli currently has a “Buy” rating and a $142.00 target price on the stock. Gabelli also issued estimates for Zimmer Biomet Holdings’ FY2020 earnings at $10.65 EPS.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. During the same quarter last year, the firm earned $2.02 EPS. The company’s revenue was up 1.1% on a year-over-year basis. TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/27/equities-analysts-offer-predictions-for-zimmer-biomet-holdings-inc-s-fy2019-earnings-zbh.html.

ZBH has been the subject of a number of other reports. Goldman Sachs Group, Inc. (The) started coverage on Zimmer Biomet Holdings in a research note on Tuesday, May 16th. They issued a “sell” rating and a $92.00 target price for the company. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 8th. Morgan Stanley upped their target price on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a research note on Monday, July 17th. Oppenheimer Holdings, Inc. set a $137.00 target price on Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Monday, August 14th. Finally, BMO Capital Markets restated a “buy” rating and issued a $136.00 target price on shares of Zimmer Biomet Holdings in a research note on Tuesday, July 11th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Zimmer Biomet Holdings has an average rating of “Hold” and a consensus price target of $136.75.

Zimmer Biomet Holdings (ZBH) opened at 113.19 on Friday. Zimmer Biomet Holdings has a 12-month low of $95.63 and a 12-month high of $133.49. The firm’s 50-day moving average is $120.75 and its 200 day moving average is $120.97. The firm has a market cap of $22.89 billion, a PE ratio of 32.24 and a beta of 1.20.

Hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its position in Zimmer Biomet Holdings by 4.1% in the second quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock valued at $2,236,657,000 after buying an additional 679,080 shares in the last quarter. Vanguard Group Inc. raised its position in Zimmer Biomet Holdings by 2.6% in the second quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock valued at $1,718,057,000 after buying an additional 339,106 shares in the last quarter. State Street Corp raised its position in Zimmer Biomet Holdings by 2.4% in the first quarter. State Street Corp now owns 8,193,165 shares of the medical equipment provider’s stock valued at $1,000,463,000 after buying an additional 191,747 shares in the last quarter. Longview Partners Guernsey LTD raised its position in Zimmer Biomet Holdings by 4.4% in the second quarter. Longview Partners Guernsey LTD now owns 6,377,711 shares of the medical equipment provider’s stock valued at $818,898,000 after buying an additional 269,184 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in Zimmer Biomet Holdings by 25.0% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock valued at $602,159,000 after buying an additional 987,398 shares in the last quarter. 82.84% of the stock is owned by hedge funds and other institutional investors.

In other news, VP Tony W. Collins sold 16,986 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sang Yi sold 17,731 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. Corporate insiders own 1.07% of the company’s stock.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. The ex-dividend date is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Earnings History and Estimates for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.